We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Israel’s Teva Pharmaceutical has received marketing authorisation from the European Commission (EC) for Ajovy (fremanezumab), an injection intended to provide relief from migraines.
Mylan and Fujifilm Kyowa Kirin Biologics announced the European Commission (EC) has granted marketing authorization for Hulio, a biosimilar to AbbVie's Humira (adalimumab), for all indications.